Taken together, our results, along with those from studies that have demonstrated the neuroprotective effects of CX3CL1 [34, 35, 37, 49, 69], support the use of exogenous sCX3CL1 to inhibit microglia activation for the treatment of RP. The gene discussed is CX3CL1; the disease is retinitis pigmentosa 1.